

BELGIUM@BIO, SAN DIEGO, USA

BELGIAN PAVILION, BOOTH # 2111

\ TABLE OF CONTENTS

| INTRODUCTION | 3 |
|---|----|
| BELGIAN COMPANIES AT BIO 2017 DIEGO | 4 |
| ORGANIZERS BELGIAN DELEGATION AT BIO 2017 | 38 |
| PARTNERS BELGIAN DELEGATION AT BIO 2017 | 42 |
| TRADE & INVESTMENT OFFICES | 44 |

\ INTRODUCTION

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

Not only **extensive life sciences facilities** support this high-level technology industry but also **financial benefits for R&D companies**, **international collaborations** that guarantee regular cash flow, **world known educational systems**, a **promising product pipeline**, and **Belgium's unique central location in Europe**.

Belgium concentrates on a small territory (30,528 km²) more than **300 life sciences companies** with biotech activities. In total, the life sciences sector employs **more than 30,000 people** (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to **healthcare**, but Belgium also has a strong representation of **agricultural** and **industrial biotech companies**.

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

\ BELGIAN COMPANIES AT BIO 2017, SAN DIEGO

| page | page |
|---|--------------------------------------|
| 2 BRIDGE | I-TECH INCUBATOR |
| AMATSIGROUP7 | ITEOS THERAPEUTICS23 |
| AMPLYCELL8 | JANSSEN RESEARCH & DEVELOPMENT |
| ANDACON8 | JLINX24 |
| APITOPE INTERNATIONAL | KU LEUVEN RESEARCH & DEVELOPMENT24 |
| ARGENX9 | MASTHERCELL25 |
| ASCLEPIA | MYCARTIS25 |
| ATOMS & ART10 | NAUTADUTILH26 |
| BIOCARTIS | NLO |
| BIOMEDICAL SYSTEMS | NOVADIP BIOSCIENCES27 |
| BIO-SOURCING12 | NOVOSANIS27 |
| BIOTURNKEY | ONCODNA |
| BIRD & BIRD LLP | ONTOFORCE |
| CELYAD | OPEN WORLDWIDE INNOVATION NETWORK 29 |
| CENTRE FOR DRUG DESIGN & DISCOVERY14 | PDC* LINE PHARMA |
| CLINITUDE | PHARA |
| CMAST15 | PHARMAFLUIDICS |
| CONFO THERAPEUTICS | PMV31 |
| CSM CLINICAL SUPPLIES MANAGEMENT EUROPE. 16 | PRODIGEST |
| CURAVAC | PROMETHERA BIOSCIENCES |
| DE CLERCQ & PARTNERS | ROUSSELOT32 |
| DELPHI GENETICS | SYNGULON |
| DENYS RESEARCH CONSULTANTS18 | TIGENIX |
| DROIA | TOXIKON EUROPE |
| EUROGENTEC | UCB34 |
| FLUIDDA19 | UNIVERCELLS |
| GALAPAGOS | VIB35 |
| GHENT UNIVERSITY TECH TRANSFER20 | WBC (BIOTECH COACHING SA) |
| GSK VACCINES | XPANDINNOVATION |
| ICOSA EUROPE | XPRESS BIOLOGICS |

IMPROVEMENTATWORK......22

\ WHAT ARE YOU LOOKING FOR?

| BIOTECHNOLOGY - THERAPEUTICS | |
|--|------------------|
| ### APPLICATION ### APPLICATIO | I-TECH INCUBATOR |
| BIOTECHNOLOGY - OTHER | |
| AMPLYCELL8 ONCODNA .28 ROUSSELOT .32 | SYNGULON |
| INVESTOR | |
| DROIA | PMV31 |
| MEDICAL TECHNOLOGY | |
| BIOCARTIS | MYCARTIS |
| PHARMA | |
| GSK VACCINES | UCB34 |

\ WHAT ARE YOU LOOKING FOR?

| PROFESSIONAL SERVICES & CONSULTING | | _ |
|--|--|----------------------|
| 2 BRIDGE | IMPROVEMENTATWORK | 24 26 26 28 |
| ICOSA EUROPE | XPANDINNOVATION | 36 |
| PUBLIC / NON-PROFIT ORGANISATIONS | | |
| BIO.BE/ESSENCIA43 | KU LEUVEN RESEARCH & DEVELOPMENT | 24 |
| BIOWIN39 | LIFETECH BRUSSELS | 41 |
| BRUSSELS INVEST & EXPORT39 | OPEN WORLDWIDE INNOVATION NETWORK | 29 |
| CENTRE FOR DRUG DESIGN & DISCOVERY14 | VIB | 35 |
| FLANDERS INVESTMENT & TRADE | WALLONIA EXPORT INVESTMENT AGENCY – AWEX WALLONIA REGION TECHNOLOGY DEVELOPMENT DEPARTMENT. | |
| R&D SERVICES | | |
| AMATSIGROUP. .7 ANDACON. .8 ASCLEPIA .10 | CLINITUDE | |
| | | |

SUPPLIER & ENGINEERING

CSM CLINICAL SUPPLIES MANAGEMENT EUROPE. 16

\ 2 BRIDGE



Rodendijk 60X • BE-2980 ZOERSEL T +32 479 90 03 57 www.2bridge.be **2 Bridge** provides multi-disciplinary services in drug discovery, pre-clinical, CM&C and clinical development, registration and post-approval support.

The **2 Bridge** 'core' team has expertise within three key domains: • Translational science

- Clinical program and study management
- CM&C chemical and formulation development and registration

Our services include: • Drug Development Strategy & Project Management • Due Diligence & Opportunity Scouting • Coaching & Training

Category: Professional Services & Consulting

Delegate: Ann MEULEMANS, CEO & Managing Partner • ann.meulemans@2bridge.be

\ AMATSIGROUP



Technologiepark 4 • BE-9052 GHENT T +32 9 241 11 05 www.amatsigroup.com

Amatsigroup is a Contract Development Manufacturing Organization offering a broad range of integrated services to pharmaceutical and biotechnology companies with respect to:

- Biologicals: Process development, cGMP manufacturing including fill and finish Bioservices Pharmaceutical Analysis Solutions
- Formulation Development and Manufacturing: development of innovative drug delivery system for small molecules and biologicals Clinical Trial Supply: Packaging and Logistics.

Category: R & D Services

Delegates: Annie VAN BROEKHOVEN, CEO amatsiQBiologicals • a.vanbroekhoven@amatsigroup.com

Karine CLAUWAERT, Director Business Development amatsiQBiologicals •

k.clauwaert@amatsigroup.com

Jody VOORSPOELS, CSO amatsiSEPS • j.voorspoels@amatsigroup.com

\ AMPLYCELL



Amplycell has developed stimulation technologies that activates cell lines metabolism in order to get higher yield of monoclonal antibody and recombinant protein productions up to 10 times.

Category: Biotechnology - Other

Avenue Hippocrate 5 • BE-4000 LIEGE T +32 42 66 94 93 www.amplycell.com

Delegates: Geoffry HOLSBEEK, CEO • geoffrey.holsbeek@amplycell.com

Julien ISOARD, Business Development • julien.isoard@amplycell.com

\ ANDACON



Andacon is a specialty pharmaceutical and services company active in Clinical Trials (sourcing comparators) and Unmet Medical Need Programs (name patient supply).

Category: R & D Services

Beselarestraat 72 • BE-8890 DADIZELE T +32 56 54 00 85 www.andacon.com

Delegate: Thomas OCKIER, Managing Director • thomas.ockier@andacon.com

\ APITOPE INTERNATIONAL

apitope

Development of highly selective immunotherapies for autoimmune diseases. Interested in outlicensing programmes and also in discovery alliances for autoimmune antigen targets of interest.

Category: Biotechnology - Therapeutics

Agoralaan A-Bis • BE-3590 DIEPENBEEK T +44 79 19 14 49 01 www.apitope.com

Delegate: Hayley FRENCH, Commercial Director & General Counsel • hayley.french@apitope.com

ARGENX



argenx develops novel human medicines to unlock novel and complex targets addressing diseases that are underserved by current therapies. We combine our unique antibody discovery platform, SIMPLE Antibody™ with Fc engineering technologies to create highly differentiated antibodies with distinctive therapeutic qualities.

Category: Biotechnology - Therapeutics

Industriepark Zwijnaarde 7, Building C • BE-9052 GHENT T +32 9 310 34 00

www.argenx.com

Debbie ALLEN, Senior VP Business Development • dallen@argenx.com Delegate:

\ ASCLEPIA



Asclepia offers medicinal chemistry oriented research and services by designing and delivering innovative, therapeutically relevant, drug-like compounds, from early stage discovery till IND package.

Category: R & D Services

Damvalleistraat 49 • BE-9070 DESTELBERGEN T +32 468 13 70 14 www.asclepia.com

Delegate: Frederik DEROOSE, CEO • frederik.deroose@asclepia.com

\ ATOMS & ART



Atoms & art is building on its expertise in international business development, cross-functional projects and medico-marketing to pursue technologies and partnering opportunities.

We are flexible to a variety of therapeutic areas with particular expertise and network in Regenerative Medicine, immune-mediated diseases, orthopedics, rare diseases, inflammatory bowel diseases, rheumatoid diseases, critical care and cellular therapies.

Category: Professional Services & Consulting

Grote Markt 12 bus 3 • BE-3200 AARSCHOT T +32 494 57 81 22

www.atomsandart.com

Delegates: Leen LIMBOURG, Founding Partner • leen@atomsandart.com

Robert DEKKER, Founding Partner • robert@atomsandart.com

10

\ BIOCARTIS



Biocartis (Euronext Bxl: BCART) is an innovative MDx company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Its proprietary MDx Idylla™ platform, launched in Sept 2014, is a fully automated sample-to-result, real-time Polymerase Chain Reaction system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting.

Category: Medical Technology

Generaal De Wittelaan 11B3 • BE-2800 MECHELEN T +32 15 63 26 00

www.biocartis.com

Delegate: Erik VOSSENAAR, Business Development Director • evossenaar@biocartis.com

\ BIOMEDICAL SYSTEMS



Biomedical Systems is a premier global provider of centralized diagnostic services. Founded in 1975, Biomedical Systems has grown to be a leading clinical trial service provider to pharmaceutical, medical device, biotech, and contract research organizations (CROS). Our comprehensive clinical trial solutions include cardiac safety, pulmonary function, imaging, electronic clinical outcome assessment (eCOA/ePRO) and scientific affairs

Category: Professional Services & Consulting

Waversesteenweg 1945 • BE-1160 BRUSSELS T +32 2 661 20 70

www.biomedsys.com

Delegate: Erik FALVEY, TBC Director, Alliances & Partnerchips • efalvey@biomedsys.com

\ BIO-SOURCING



Bio-Sourcing aims to harness nature's power to produce large quantities of specific proteins in milk in order to increase the availability of drugs for animal health.

Category: Biotechnology - Therapeutics

Avenue Hippocrate 5 • BE-4000 LIEGE T +32 497 48 51 22 www.bio-sourcing.com

Delegate: Bertrand MEROT, CEO • bertrand.merot@bio-sourcing.com

\ BIOTURNKEY



cGMP and Clinical readiness through disruptive closed system devices powered by 20+ year manufacturing expertise. US/UE **BIOTURNKEY** offers total quality anytime anywhere at a fraction of the costs.

Category: Medical Technology

Rue de la Science 8 • BE-6900 AYE T +32 486 13 58 57 www.bioturnkey.com

Delegates: Frédéric TONGLET, CEO • ftonglet@bioturnkey.com

François LESAGE, CBO • flesage@bioturnkey.com

\ BIRD & BIRD LLP

Bird & Bird

Louizalaan 235, B1 • BE-1050 BRUSSELS T +32 2 282 60 00

marc martens@twobirds.com

www.twobirds.com

Delegate: Marc MARTENS, Partner/Head of International Life Sciences & Healthcare Group •

Bird & Bird's internationally renowned Life Sciences & Healthcare group can guide you through every aspect of the life cycle of innovative life sciences products and services. We work with over 50% of the world's largest pharmaceutical companies and with over 240 lawyers globally and a wealth of hands-on experience from working in industry and regulatory bodies, clients choose us as their strategic partner to guide them through some of their most complex legal challenges.

Category: Professional Services & Consulting

\ CELYAD



Rue Edouard Belin 2 BE-1435 MONT-SAINT-GUIBERT T +32 10 39 41 00 www.celyad.com

Delegate: Georges RAWADI, Business Development and IP • grawadi@celyad.com

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized cell-based therapies targeting lifethreatening diseases. Its Natural Killer Receptor based T-Cell platform has the potential to treat a broad range of solid & hematologic tumors. Its lead oncology candidate, CAR-T NKR-2, is being evaluated in the THINK open-label Phase I study to assess the safety & clinical activity of multiple administrations of autologous CAR-T NKR-2 cells in 7 refractory cancers.

Category: Biotechnology - Therapeutics

\ CENTRE FOR DRUG DESIGN & DISCOVERY

Centre for Drug Design and Discovery



Gaston Geenslaan 2 • BE-3001 LEUVEN T +32 16 32 64 84 www.cd3.eu

The Centre for Drug Design and Discovery (CD3) translates innovative science into promising drug discovery programs that are well qualified for further development by pharmaceutical or biotech companies. CD3 brings expert drug discovery capabilities and financial means to academic research groups and small companies in order to discover innovative small molecule drugs. Supported by KU Leuven Research & Development and the European Investment Fund, CD3 launched a 60 million euro fund in 2016.

Category: Public / Non-Profit Organisations

Delegates: Patrick CHALTIN, Managing Director • patrick.chaltin@kuleuven.be

Stefaan ALLEMEERSCH, Director Business Development •

stefaan.allemeersch@cistim.be

\ CLINITUDE



Alfons Smetsplein 3H1 • BE-3000 LEUVEN T +32 16 58 19 84 www.clinitude.com

Clinitude is a privately owned CRO with more than 10 years of experience, specialized in cross-border clinical research consultancy with in depth experience in submitting and monitoring clinical trials in Europe and Asia. Handling the diversity and complexity in local laws and regulations for each country is one of our expertises. Clinitude is unique in an environment where delays and cost overruns are considered normal, while we guarantee a cost effective efficient timely approach.

Category: R & D Services

Delegates: Sabrina WIJNEN, Managing Director • sabrina@clinitude.com

Gert MONNISSEN, Joint Managing Director • gert@clinitude.com

14

\ CMAST



CMAST is a specialized consultancy and project management service provider in the domain of R&D, Innovation and Supply Chain within the Life Sciences industry.

Category: Professional Services & Consulting

Georges Van Dammeplein 57 • BE-9140 TEMSE T +32 498 10 65 35 www.c-mast.com

Delegate: Glenn VAN DAEL, Managing Director • glenn.van.dael@c-mast.com

\ CONFO THERAPEUTICS



Rijvisschestraat 120 • BE-9052 GHENT T +32 2 629 14 53

www.confotherapeutics.com

Delegate: Cedric VERVERKEN, CEO • cedric.ververken@confotherapeutics.com

Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary Confo® technology to lock inherently unstable functional conformations of GPCRs as a superior starting point for drug discovery. Confo® body-stabilized active state conformations of these receptors expose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.

Category: Biotechnology - Therapeutics

CSM CLINICAL SUPPLIES MANAGEMENT **EUROPE**



Watson & Crick Hill T +32 10 23 74 44

http://csmondemand.com

BMS: • Design & Assembly of Collection Kits • Rue Granbonpré 11 **BMS logistics & Biorep BE-1435 MONT-SAINT-GUIBERT** Category: Supplier & Engineering

Drugs . Ancillary Supplies

CSM is a global Clinical Supply services company. Since 1997 CSM has serviced over 1,000 of clinical studies that span across a wide range of therapeutic areas globally. Our 2 core business lines to support PhI to IV Clinical Trials are: CTS: • Primary and Secondary Packaging & Labelling • QP Release • Warehousing & Distribution • Project Management • Coordination of Transportation • Sourcing

David FONTAINE, Chief Business Development Officer • dfontaine@csmondemand.com

CURAVAC



Therapeutic Vaccines for Autoimmune Diseases

Avenue de Villefranche 80 BE-1330 RIXENSART T +32 2 686 04 45 www.curavac.com

Delegates: Stéphane HUBERTY, CEO • mail@curavac.com

Nicolas HAVELANGE, COO • n.havelange@curavac.com

CuraVac - Therapeutic Vaccines and Immunotherapies for Autoimmune Diseases.

CuraVac is a biotech company developing therapeutic vaccines and active targeted immunotherapies for autoimmune diseases. The first product, Designated Orphan Drug, has shown safety and indication of efficacy in a phase 1b on patients suffering from myasthenia gravis. Phase 2/3 is starting now with expected results at the end of 2018.

CuraVac is looking for financing, strategic alliances & geographic licensing deals.

Category: Biotechnology - Therapeutics

BELGIUM@BIO USA JUNF 19-22, 2017

\ DE CLERCQ & PARTNERS

De Clercq&partners

Edgard Gevaertdreef 10a BE-9830 SINT-MARTENS-LATEM T +32 9 280 23 40 www.dcp-ip.com De Clercq & Partners is an established firm of experienced Patent and Trademark and Design attorneys providing a full range of Intellectual Property and legal services. The firm has a very strong expertise in life sciences and thrives on a highly specialized and experienced group of over thirty-five enthusiastic experts that have a common aim to serve clients to the highest standards for very competitive prices in a European setting.

Category: Professional Services & Consulting

Delegates: Koen VANHALST, European Patent Attorney • koen.vanhalst@dcp-ip.com
Andrej MICHALÍK, European Patent Attorney • andrej.michalik@dcp-ip.com

DELPHI GENETICS



Delphi Genetics is providing Technology and Flexibility in Bioproduction of plasmid DNA and recombinant proteins including antibodies. These productions are performed based on robust antibiotic free process and technology. Plasmid DNA productions are available in R&D and High Quality grades and soon in GMP grade, certification is pending.

Category: Biotechnology - Therapeutics

Rue Antoine de Saint-Exupery 5 • BE-6041 GOSSELIES T +32 71 25 10 00

www.delphigenetics.com

Delegates: Marc DECHAMPS, Managing Director • mdechamps@delphigenetics.com
Thierry VAN REETH, Scientific & Sales Manager • tvanreeth@delphigenetics.com

DENYS RESEARCH CONSULTANTS



Kantestraat 5 • BF-8700 KANEGEM T +32 51 67 91 10 www.drc-bvba.be

well-established full service clinical research organization (CRO) offering high quality clinical development services for the academic research, pharmaceutical, biotech and medical devices industry. Together with our strategic partner 2Bridge our services go from drug development strategy over due diligence and opportunity scouting to full clinical trial services in project management and monitoring for Phase I through Phase IV clinical trials.

Denys Research Consultants (DRC) is a dynamic,

Category: Professional Services & Consulting

Delegate: Stijn OTTE, Director Business Development • stijn.otte@drc-bvba.be

DROIA



DROIA Oncology Ventures is a hands-on investor with an exclusive focus on development of new oncology therapies with breakthrough potential. We are dedicated to making a difference in the fight against cancer and have adopted a unique investment model to accelerate development in our portfolio companies.

The holding is funded by European private investors, and operates from offices in Luxembourg and Brussels. We invest worldwide.

Category: Investor

Brusselsesteenweg 11 • BE-1860 MEISE T +32 2 880 67 30

www.droiagroup.com

Delegate: Bart VAN HOOLAND, Managing Partner • bart.vanhooland@droiagroup.com

BELGIUM@BIO USA

\ EUROGENTEC



Eurogentec is an FDA inspected CMO, that offers GMP contract manufacturing of proteins, conjugates, and plasmids for clinical and commercial supply.

Category: Biotechnology - Therapeutics

Rue Bois Saint-Jean 5 • BE-4102 SERAING T +32 4 372 74 00

www.eurogentec.com

Delegate: Pascal BOLON, Biologics Sales and Marketing Manager • p.bolon@eurogentec.com

\ FLUIDDA



Groeningenlei 132 • BE-2550 KONTICH T +32 3 450 87 20

www.fluidda.com

Delegate: Charles MUSSCHE, Business Development US • dd@fluidda.com

FLUIDDA is the world leader in the field of Functional Respiratory Imaging (FRI) research and development. The company's proprietary FRI technology offers pharmaceutical companies and healthcare providers a unique entry point into personalized medicine for patients suffering from respiratory diseases and sleep-related breathing disorders. Implementation of FRI in the clinical practice creates significant added value to the current healthcare standard in the respiratory field.

Category: Medical Technology

\ GALAPAGOS



Galápagos

Gen. De Wittelaan L11 A3 BE-2800 MECHELEN T +32 15 34 29 00 www.glpg.com Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. We seek to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biotechnological company, focused on the development and commercialization of novel medicines that will improve people's lives.

Category: Biotechnology - Therapeutics

Delegates: Andre HOEKEMA, SVP Corporate Development • andre@glpg.com

Paul VAN DER HORST, Director Business Development • paul.vanderhorst@glpg.com

\ GHENT UNIVERSITY TECH TRANSFER



As the **Tech Transfer Office of Ghent University**, we provide support with licensing, IP transfer and collaboration projects as well as patent prosecution.

Category: Public / Non-Profit Organisations

iGent Tower
Technologiepark 15 • BE-9052 GHENT
T +32 9 264 78 83
www.ugent.be/techtransfer/en

Delegates: Philippe JACOBS, European Patent Attorney • philippe.jacobs@ugent.be

Piet DE VOS, Licensing Manager • piet.devos@ugent.be

20

\ GSK VACCINES



panies, with a broad portfolio of 41 paediatric, adolescent, adult, older people and travel vaccines, and 14 candidate vaccines in our pipeline. We have more than 16,000 people working worldwide to deliver over 2 million doses of vaccines per day to people in more than 160 countries. **GSK** is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

GSK is one of the world's leading vaccine com-

Category: Pharma

Rue de l'Institut 89 • BE-1330 RIXENSART T +32 2 656 81 11

www.gsk.com

Delegate: Philippe DENOEL, Head of External R&D • vaccinespartnering@gsk.com

\ ICOSA EUROPE



Clos Chapelle-aux-Champs 30 Postal box 1.30.30 BE-1200 BRUSSELS T +32 2 880 62 48 www.icosa.fr

Delegates: Claire VERSCHELDE, Partner • verschelde@icosa-europe.com

Caroline de MAREÜIL-VILETTE, Partner • demareuil@icosa-europe.com

ICOSA is a European, French and Belgian Patent Attorney Firm dedicated to Healthcare and specialized in Life Sciences, Chemistry and MedTech. ICOSA takes part in each step of the lifetime of the patent and advises its clients on all aspects of IP. ICOSA provides in particular guidance from patent protection, IP strategy to valuation of IP assets including IP audit for fundraising. ICOSA also protects innovation of its clients all over the world thanks to its international IP network.

Category: Professional Services & Consulting

IMPROVEMENTATWORK



Our expertise is in supporting small biotech/pharma companies in their first submission to FDA/EMA (or other HA) in a cross functional, global environment and be prepared as such that this can be done in a short timeframe. This will lead to faster approval and time to market.

Category: Professional Services & Consulting

Du Boislei 31 • BE-2930 BRASSCHAAT T +32 474 55 05 97

www.improvementatwork.be

Delegate: Johan TELEN, Managing Partner • johan.telen@improvementatwork.be

\ I-TECH INCUBATOR



Auguste Piccard Street 48
BE-6041 GOSSELIES
T +32 71 91 99 50
www.i-tech-incubator.be

i-Tech Incubator Incubator is an incubation structure. It offers a "one-stop-shopping" platform through a full range of services offered by its various activities. i-Tech Incubator Incubator was created to help and host technology companies. The aim is to facilitate the transformation of an idea into a real business, while provid a high quality hosting service, simplify the work of entrepreneurs so they can better focus on the essentials: the development of their business.

Category: Biotechnology - Therapeutics

Delegates: Marie BOUILLEZ, Managing Director • marie@i-tech-incubator.be

Florence BOSCO, CEO • florence@i-tech-incubator.be

BELGIUM@BIO USA
JUNE 19-22, 2017

ITEOS THERAPEUTICS



Rue des Frères Wright 29/3 BE-6041 GOSSELIES T +32 71 91 99 33 www.iteostherapeutics.com Based in Gosselies, Belgium, iTeos, a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL), is focused on expanding the benefits of immunotherapy for cancer patients. The company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-inflamed tumors. It has licensed its IDO1 program, now in Phase 1 development, to Pfizer. iTeos' competitive edge is in the combination of expertise in drug discovery and translational tumor immunology. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development).

Category: Biotechnology - Therapeutics

Delegate: Michel DETHEUX, CEO on behalf MG6A • Michel.detheux@iteostherapeutics.com

JANSSEN RESEARCH & DEVELOPMENT



Turnhoutseweg 30 • BE-2340 BEERSE T +32 14 60 21 11

www.janssen.com/belgium

Delegate: Frederik WITTOCK, Director, EMEA Communications • fwittock@its.jnj.com

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. Follow us at @ Janssen Global. One of the most prominent Janssen companies is the Belgian company Janssen Pharmaceutica located in Beerse, Geel, Olen. La Louvière and Merksem.

Category: Pharma

\ JLINX

Johnson Johnson INNOVATION JLINX

J&J Innovation launched JLINX in 2016 in partnership with Bioqube Ventures. JLINX is an investment/incubation model designed to nurture early stage companies. We offer them a spectrum of resources to grow and collaborate across the European life science ecosystem. JLINX aims to catalyze scientific advances and accelerate breakthroughs. JLINX is located on the Janssen R&D site in Beerse, Belgium. Supported through the European Regional Development Fund and by the Flemish Government.

Category: Professional Services & Consulting

Turnhoutseweg 20 • BE-2340 BEERSE T +32 476 92 50 77 www.injinnovation.com/jlinx

Delegate: Frederik WITTOCK, Director, EMEA Communication • fwittock@its.jnj.com

\ KU LEUVEN RESEARCH & DEVELOPMENT



Waaistraat 6 box 5105 • BE-3000 LEUVEN T +32 16 32 65 00

http://lrd.kuleuven.be/en

KU Leuven Research & Development (LRD) is dedicated to building bridges between science and industry. By transferring knowledge and technologies to society and the marketplace, LRD advances the impact of research results on people's lives around the globe. Established in 1972, LRD has developed a solid tradition of collaborating with industry, securing and licensing intellectual property rights, creating spin-off companies and stimulating knowledge-driven regional development.

Category: Public / Non-Profit Organisations

Delegates: Patrick CHALTIN, Managing Director CD3 • patrick.chaltin@kuleuven.be

Stefaan ALLEMEERSCH, Director Business Development •

stefaan.allemeersch@cistim.be

24

MASTHERCELL



Rue Auguste Piccard 48 BE-6041 GOSSELIES T +32 71 34 76 29 www.masthercell.com MaSTherCell is a dynamic and global Contract Development and Manufacturing Organization (CDMO) on a mission to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market. From technology selection to GMP manufacturing, process development, quality management and assay development. MaSTherCell's teams are fully committed to helping their clients provide sustainable and affordable therapies to their patients.

Category: Biotechnology - Therapeutics

Delegates: Jesse TREKKER, Business Developer • jesse.trekker@masthercell.com
Denis BEDORET, General Manager • denis.bedoret@masthercell.com

\ MYCARTIS



Technologiepark 4 • BE-9052 GHENT T +32 9 241 11 40 www.mycartis.net

Delegates: Joris SCHUURMANS, CEO • info@mycartis.net

François TOPIN, SVP Commercial Operations • ftopin@mycartis.net

MyCartis delivers an innovative diagnostic platform, Evalution™, for fast, highly sensitive and cost effective identification of a patient's biomarker signature, providing precise and personalized data for medical decision making. MyCartis, a front-runner in biomarker analysis, offers the next generation biomarker analysis platform. MyCartis is about to commercialize its platform and therefore establishing partnerships to develop new or to improve existing assays based on its unique technology.

Category: Medical Technology

\ NAUTADUTILH

• NautaDutilh

Chaussée de la Hulpe 120 BE-1000 BRUSSELS T +32 2 566 80 00 www.nautadutilh.com We provide legal services to pharma, biotech and medical devices companies. From universities and their spin-offs to mature organisations and from professional associations to investors. At NautaDutilh, we provide the complete range of transactional, advisory and litigation services - from commercial agreements and mergers & acquisitions to patent litigation, marketing authorisation procedures, and pricing and reimbursement decisions - tailored to meet our clients' specific needs.

Category: Professional Services & Consulting

Delegates: Jo VANWITTENBERGH, Marketing & BD responsible •

jo.vanwittenbergh@nautadutilh.com

Elke JANSSENS, Partner • elke.janssens@nautadutilh.com

\ NLO



Technologiepark 19 • BE-9052 GHENT T +32 9 240 98 88 www.nlo.eu/be

NLO is one of the largest and most prominent Intellectual Property consultancies in Europe. We protect and reinforce our clients' ideas, innovations and trademarks bearing in mind the markets in which they are involved. We offer IP services over a broad area (patents in all aspects, trademarks, designs, agreements and IP administrative services). With offices in the Netherlands and Belgium and over 70 patent and trademark attorneys, we have expertise in many technical domains.

Category: Professional Services & Consulting

Delegates: Caroline PALLARD, Dutch and European Patent Attorney • pallard@nlo.eu

Emil POT, European Patent Attorney • pot@nlo.eu

Peter ten HAAFT, Dutch and European Patent Attorney • tenhaaft@nlo.eu

26

NOVADIP BIOSCIENCES



Rue Granbonpré 11 BE-1435 MONT-SAINT-GUIBERT T +32 10 77 92 20 www.novadip.com **Novadip** is a biopharmaceutical company founded to develop innovative stem cell-based therapies adapted for regenerative medicine. **Novadip** pioneers the growth of 3-D tissues derived from adipose-derived stem cells to regenerate bone and soft tissues. NVD-001 is a revolutionary, ready-to-use and biological 3D osteogenic structure that can be modelled to fill large and small bone defects. NVD-002 is a biological bandage for skin tissue applications, designed to avoid formation of painful scars.

Category: Biotechnology - Therapeutics

Delegate: Jean-François POLLET, CEO • jean-francois.pollet@novadip.com

NOVOSANIS



Bijkhoevelaan 32c • BE-2110 WIJNEGEM T +32 3 485 50 16 www.novosanis.com **Novosanis** is a Belgian innovative developer and producer of medical devices (ISO13485 certified) adding value to the accuracy of diagnostics tests as well as drug delivery in the field of prevention, detection and treatment of infectious diseases and oncology.

We have two business units: (1) Delivery Solutions (VAX-ID platform for intradermal drug delivery); (2) Sampling Solutions (Colli-Pee platform for collection of first-void urine).

Category: Medical Technology

Delegates: Vanessa VANKERCKHOVEN, CEO • vanessa.vankerckhoven@novosanis.com

Koen BEYERS, CTO • koen.beyers@novosanis.com

\ ONCODNA



OncoDNA, The Cancer Theranostic Company, is the European leading oncology company providing solutions for cancer treatments, at the same time contributing to the knowledge applied to the fight against cancer. OncoDNA's team is fully dedicated to help oncologists worldwide developing services to enable better treatment choices and treatment efficacy monitoring.

Category: Biotechnology - Other

Rue Louis Breguet 1 • BE-6041 GOSSELIES T +32 71 18 35 00 www.oncodna.com

Jean-Pol DETIFFE, CEO & Founder • jp.detiffe@oncodna.com

\ ONTOFORCE



Ottergemsesteenweg-Zuid 808 BE-9000 GHENT T +32 9 330 91 55 www.ontoforce.com

ONTOFORCE is a life sciences and health IT company specialized in linked data technology for advanced data mining.

Our user-friendly online search application, DISQOVER, is driven by semantic technology building intelligent links across multiple heterogeneous internal and external data sources providing high accuracy and easy access to real time information beyond traditional data providers. This results in significant time savings, enables better decision making and drives innovation forward.

Category: Professional Services & Consulting

Delegates: Hans CONSTANDT, CEO and Founder • hans@ontoforce.com

Filip PATTYN, Scientific Lead • filip@ontoforce.com

\ OPEN WORLDWIDE INNOVATION NETWORK



Raymond Stotzer Pkwy 800 - Ste 2020 UNITED STATES - 77845 - 6151 TEXAS T +32 474 92 64 18

www.openiwin.com

Delegate: Amaëlle HAULET, Executive Director • amaelle.haulet@openiwin.com

OWIN - Open Worldwide Innovation Network is a consortium of the world-renowned research Universities, TTOs and Trade Agencies encouraging a global culture of innovation and entrepreneurship. OWIN fosters win-win opportunities and helps companies grow faster in its members markets (Australia, Belgium, China and the USA) by assessing technologies, identifying commercial and strategic partnerships, coordinating ioint-ventures and much more.

Category: Public / Non-Profit Organisations

\ PDC* LINE PHARMA



Creapole Allée des Noisetiers 21 • BE-4031 ANGLEUR T +32 42 42 77 56

www.pdc-line-pharma.com

Delegates: Eric HALIOUA, President & CEO • e.halioua@pdc-line-pharma.com

Laurent LEVY, COO • I.levy@pdc-line-pharma.com

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma (www.pdc-line-pharma.com) is a Belgian biotech company that develops a new class of potent and scalable therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Unlike conventional autologous DC, PDC*line is a highly scalable off-the-shelf product. PDC*vac is applicable to any cancer type, very versatile and could be synergistic with immune checkpoint inhibitors.

Category: Biotechnology - Therapeutics

\ PHARA



PhaRA is a consultancy firm in EU Regulatory Affairs providing strategic and hands-on support to Pharma & Biotech companies (CTA, PIP, Orphan Drug, Scientific Advice, CP/DCP/MRP, MAA, Life Cycle Management etc.).

Category: Professional Services & Consulting

Roosevelt Building Anneessensstraat 3-5 B9 • BE-2018 ANTWERP T +32 3 293 90 84 www.phara-consulting.be

www.piiaia-consulting.be

Delegate: Ingrid THEEUWES, Managing Director • i.theeuwes@phara-consulting.be

\ PHARMAFLUIDICS



PharmaFluidics develops and commercializes micro-chip based chromatography cartridges with unprecedented analytical resolution performance. PharmaFluidics' µPAC(R) cartridges allow to detect more and rarer molecules in tiny, complex biological samples; they are used for applications in bio-medical research, for instance for the development of bio-markers or bio-pharmaceutical drugs.

Category: Medical Technology

Technologiepark 3 • BE-9052 GHENT T +32 9 241 56 57 www.pharmafluidics.com

Delegate: Johan DEVENYNS, Managing Director • johan.devenyns@pharmafluidics.com

BELGIUM@BIO USA
JUNE 19-22, 2017

\ PMV



Oude Graanmarkt 63 • BE-1000 BRUSSELS T +32 2 229 52 30

www.pmv.eu

PMV is a Private Equity investor with a Venture Capital franchise in Life Sciences. We invest in highly innovative companies with the potential to generate financial return both for our funds and the region of Flanders. Being a very active investor, PMV helps building businesses by investing in both early- and growth stage companies in all areas of biotech and healthcare. Our current portfolio includes leading biotech companies, such as Biocartis, eTheRNA, Complix, Feops, argenx and Celyad.

Category: Investor

Delegate: Alexandra TOLIA, Senior Investment Manager • alexandra.tolia@pmv.eu

\ PRODIGEST



Technologiepark 3 • BE-9052 GHENT T +32 9 241 11 90 www.prodigest.eu

Delegate: Kristof VAN EMELEN, CSO • kristof.vanemelen@prodigest.eu

ProDigest is a product leader in the development of unique laboratory models of the human and animal gastrointestinal tract (SHIME®). Complementary to in vivo studies, these models allow to obtain insight in gut processes associated to the intestinal fate of actives. ProDigest is globally active as a service provider for food and pharmaceutical companies. Furthermore, ProDigest has set up a number of in-house product development projects in relation the development of novel biotherapeutics.

Category: R&D Services

PROMETHERA BIOSCIENCES



Rue Granbonpré 11 BE-1435 MONT-SAINT-GUIBERT T +32 10 39 43 00 www.promethera.com **Promethera Biosciences** is a global innovator in liver cell-based medicines whose mission is to help patients overcome acute and chronic liver diseases. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. We are a team of international experts operating out of R&D and GMP facilities in Mont-Saint-Guibert, Belgium, and Durham, NC, USA.

Category: Biotechnology - Therapeutics

Delegate: Henrik LUESSEN, PhD, Chief Business Officer • henrik.luessen@promethera.com

\ ROUSSELOT



Rousselot is recognized as the leader in the production of high quality gelatins for food, pharmaceutical and medical applications. We offer fit for use gelatins very low in endotoxin and controlled in microbiology.

Rousselot is a brand of Darling Ingredients.

Category: Biotechnology - Other

Meulestedekaai 81 • BE-9000 GHENT T +32 9 255 18 60 www.rousselot.com

Delegate: Jeroen VAN EGMOND, Business Development Director • jvanegmond@darlingii.com

BELGIUM@BIO USA
JUNE 19-22, 2017

\ SYNGULON



Microbial fermentation technologies for bio-based products

Rue des Chasseurs Ardennais 3 BE-4031 LIEGE T +32 4 290 55 45 http://syngulon.com

Delegate: Guy HELIN, CEO • ghelin@syngulon.com

Syngulon is developing original genetic technologies to improve the efficiency of microorganisms (also called microrefineries) involved in biopharma or in industrial bioproduction. At BIO, Syngulon introduces a new genetic technology (US Patent 9,333,227) focusing on the control of microorganisms for recombinant products or biocatalysis. The patent is based on the use of bacteriocin/immunity in any bacteria, yeast or algae for controlled growth of microorganisms.

Category: Biotechnology - Other

\ TIGENIX



Romeinse straat 12 bus 2 BE-3001 LEUVEN T +32 16 39 60 60 www.tigenix.com Sepsis. Our lead product completed a Phase III trial for the treatment of complex perianal fistulas in Crohn's Disease and has been recently licensed to Takeda (ex-US).

Category: Biotechnology - Therapeutics

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of

allogeneic, or donor-derived, expanded stem cells. Clinical programmes are on course in Crohn's Disease, Acute Myocardial Infarction and

Delegate: Miguel MULET, Director of Strategy and New Projects • miguel.mulet@tigenix.com

\ TOXIKON EUROPE



Romeinsestraat 12 • BE-3001 LEUVEN T +32 16 40 04 84 www.toxikon.be Toxikon is an international CRO with GMP and GLP accreditations. We contract and partner with pharma and biotech industries to deliver exceptional product development services from concept to final product. We provide in vivo capabilities ranging from Proof-of-Concept studies using animal disease models to full toxicology programs to support your IND/NDA submission. Including full analytical services for CMC and bio-analytical work. At Toxikon, we take time to design and customize your project.

Category: Professional Services & Consulting

Delegate: Kevin BREESCH, Program Manager • kevin.breesch@toxikon.be

\ UCB



Allée de la Recherche 60 BE-1070 BRUSSELS T +32 2 559 99 99 www.ucb.com global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of \in 4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB).

UCB, Brussels, Belgium (www.ucb.com) is a

Category: Pharma

Delegate: Didier MALHERBE, Vice President & Head of Public Affairs and General Manager

UCB Belgium • contactucb@ucb.com

34

\ UNIVERCELLS



Rue Auguste Piccard 48 BE-6041 GOSSELIES T +32 71 91 98 55 www.univercells.com **Univercells** is company specialized in process development with the objective of significantly reducing the cost of goods of manufacturing biological drugs.

We strive towards this by reinventing process architecture using low-footprint systems, incorporating high-density bioreactors operated in perfusion with in line purification, resulting in a dramatic reduction (up to 90%) of the cost of production.

Category: Biotechnology - Other

Delegates: **Benjamin DAMIEN**, Director of Business Development • b.damien@univercells.com **Marie JOURDAN**, Sales Engineer • m.jourdan@univercells.com

\ VIB



Rijvisschestraat 120 • BE-9052 GHENT T +32 9 244 66 11 www.vib.be

VIB is an excellence-based entrepreneurial life-sciences research institute that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications. With about 1500 scientists from over 60 countries, we perform basic research into the molecular foundations of life. VIB works in close partnership with five universities - UGent, KULeuven, University of Antwerp, Vrije Universiteit Brussel and Hasselt University - and is funded by the Flemish government.

Category: Public / Non-Profit Organisations

Delegates: Floor STAM, Business Development Manager • floor.stam@vib.be

 $\textbf{Charlotte DE VISSCHER}, \ \textbf{Business Development Manager} \bullet \textbf{charlotte.devisscher@vib.be}$

Jan DEMOLDER, European Patent Attorney • jan.demolder@vib.be

WBC (BIOTECH COACHING SA)



Avenue de l'Hôpital 11 CHU – B34 BE-4000 LIEGE T +32 4 246 51 10

www.wbc-incubator.be

Delegates: Serge PAMPFER, General Manager • pampfer@wbc-incubator.be
Frank TOUSSAINT, Project Manager • toussaint@wbc-incubator.be
Hélène LALANNE, Project Manager • Lalanne@wbc-incubator.be

WHERE LIFE SCIENCES GO BUSINESS!

WBC transforms innovation into economic and industrial value by coaching biomedical, environmental and agri-food biotech projects. We support the development of scientific and technological projects thanks to a set of generic and specific tools that cover the priority aspects of management, financing and the stages of prototyping, production and commercialization. See more on our website: www.wbc-incubator.be & follow us on twitter/@WBCBiotech.

Category: Biotechnology - Other

\ XPANDINNOVATION



Voorhavenlaan 14A • BE-9000 GHENT T +32 9 218 71 97 www.xpandinnovation.com **XpandInnovation** optimizes your company's expansion into new markets providing strategic consultancy and hands-on execution throughout your development path. We are at your side, every step of the way.

• Exposure and access to European investor networks, non-dilutive funding, licensing partners, ... • Executing and/or supervising selected R&D projects, QC, market access, supply chain, BD, sales and marketing • Set up of your EU subsidiary and staffing

Our unique process ensures continuity: transfer of knowhow combined with forward-looking planning.

Category: Professional Services & Consulting

Delegates: Ann VAN GYSEL, Partner • ann.vangysel@turnstone.com

Luc DECAT, Partner • Luc.Decat@novellashealthcare.com

Stefaan SCHATTEMAN, Partner • stefaan.schatteman@promised.be
Murielle DE ROUCK. Partner • murielle.derouck@novellashealthcare.com

36

\ XPRESS BIOLOGICS



Avenue de l'Hopital 11, B 34+3 BE-4000 LIEGE T +32 4 242 75 97 www.xpress-biologics.com **Xpress Biologics** is a contract development organization specialized in the production of Biologics, proteins and DNA, for the therapeutic and diagnostic markets.

The production scale and the quality of the biologics (R&D and GLP) are adapted for in vitro and in vivo preclinical validation of the biologics. **Xpress Biologics** processes take into account the industrial and regulatory requirements, which greatly facilitates the transfer of the project to CMOs for the production of GMP grade material.

Category: Biotechnology - Therapeutics

 ${\tt Delegates:} \quad \textbf{Marc DAUKANDT}, \ Chief \ Executive \ Officer \bullet m. daukandt@xpress-biologics.com$

Christian RODRIGUEZ, Chief Operation Officer • ch.rodriguez@xpress-biologics.com

\ ORGANIZERS BELGIAN DELEGATION AT BIO 2017

| BIOWIN | 39 |
|--|----|
| BRUSSELS INVEST & EXPORT | 39 |
| FLANDERS INVESTMENT & TRADE | 40 |
| FLANDERSBIO | 40 |
| LIFETECH.BRUSSELS | 41 |
| WALLONIA EXPORT-INVESTMENT AGENCY (AWEX) | 41 |

\ BIOWIN



Maison de l'Industrie Technologique Rue Auguste Piccard 20 • BE-6041 GOSSELIES T +32 71 91 92 85

www.biowin.org

and its mission is to support the growth and competitiveness of the sector by bringing together stakeholders participating in R&D innovative projects and/or skills development in the fields of health biotech & medtech. Our members are active in Biopharmacy & Vaccines, Cell therapy & RegMed, Biomanufacturing, Digital Health, Diagnostics (in vitro & in vivo), Radiation Applications in healthcare, Implanted & Non-Implanted Medical Devices.

BioWin is the Health Cluster of Wallonia (Belgium)

Delegates: Sylvie PONCHAUT, General Manager • sylvie.ponchaut@biowin.org

Laurence TIMMERMANS, Head of International Affairs •

Laurence.timmermans@biowin.org

\ BRUSSELS INVEST & EXPORT



Brussels Invest & Export is the foreign trade and investment agency of the Brussels-Capital Region. It aims to promote the internationalization of the Brussels economy.

Charleroisesteenweg 112 – 3rd Floor • BE-1060 BRUSSELS T +32 2 800 40 00

www.brusselsinvestexport.be

CEO: Bénédicte WILDERS

Delegate: Eric GABRYS, Brussels Region Trade Commissioner •

california@bruxellesinvestexport.be

\ FLANDERS INVESTMENT & TRADE

FLANDERS INVESTMENT & TRADE



Koning Albert II-laan 37 • BE-1030 BRUSSELS T +32 2 504 87 11

www.flandersinvestmentandtrade.be

CEO: Claire TILLEKAERTS

Delegates: Marc VAN GASTEL, Head of Department Invest • marc.vangastel@fitagency.be

Mieke PYNNAERT, Flanders Economic Representative Montréal (Canada) •

montreal@fitagency.com

Neil BELENKIE, Invest Deputy Vancouver (Canada) • vancouver@fitagency.com

Jan WAUTERS, Science and Technology Counselor Life Sciences and Nanotechnologies New York (US) • jan.wauters@fitagency.com

Raphaël PAUWELS, Flanders Economic Representative Los Angeles (US) •

losangeles@fitagency.com

\ FLANDERS.BIO



flanders.bio is the networking organization for the life sciences sector in Flanders (Belgium), with currently 330+ members. We can assist you in finding your partner within the network of life sciences actors

Flanders Investment & Trade is the government

agency supporting home-based companies doing

business abroad and foreign companies looking to set up or expand operations in Flanders, the

northern region of Belgium.

Jean-Baptiste de Ghellincklaan 13 bus 0102 • BE-9051 GHENT T +32 9 241 80 41

www.flanders.bio

Delegates: Henk JOOS, Managing Director • henk.joos@flanders.bio

Lissa VAN HECKE, Event and Management Assistant • lissa.vanhecke@flanders.bio

BELGIUM@BIO USA
JUNE 19-22, 2017

\ LIFETECH.BRUSSELS



Lifetech.brussels gathers around 150 companies, hospitals and R&D labs. By supporting startups and identifying potential synergies, the cluster drives Health, Innovation and Entrepreneurship.

The Wallonia Foreign Trade and Investment Agency is responsible for export promotion of Wallonia-based companies and foreign

investment attraction in Wallonia, Belgium.

Tour & Taxis
Avenue du Port 86c b211 • BE-1000 BRUSSELS
T +32 2 422 00 31
www.lifetechbrussels.com

Delegate: Camille MOMMER, Business Developer • cmo@impulse.brussels

\ WALLONIA EXPORT-INVESTMENT AGENCY (AWFX)



Wallonia.be

EXPORT INVESTMENT

Place Sainctelette 2 • BE-1080 BRUSSELS T +32 2 421 82 11

www.investinwallonia.be

CEO: Pascale DELCOMINNETTE

Delegates: Francis KANIA, Director Americas • f.kania@awex.be

Yaël HAUMONT, Area Manager North America • y.haumont@awex.be Bruno LUCIDI, Life Sciences Expert • blucidi@investinwallonia.be

Philippe LACHAPELLE, Director Business Development and Strategic Partnerships •

p.lachapelle@awex.be

\ PARTNERS BELGIAN DELEGATION AT BIO 2017

| BIO.BE/ESSENSCIA | 43 |
|---|----|
| WALLONIA REGION TECHNOLOGY DEVELOPMENT DEPARTMENT | 43 |

\ BIO.BE/ESSENSCIA





Blue Point Building
Boulevard A. Reyers 80 • BE-1030 BRUSSELS
T +32 2 238 98 44

www.bio.be

Delegate: Frédéric DRUCK, Secretary General • bio.be@essenscia.be

Bio.be is the Belgian association of companies active in life sciences and biotechnologies. It is part of **essenscia**, the Belgian federation for chemistry and life sciences industries.

The mission of bio.be/essenscia is to foster a supportive environment and a stable legal framework in line with the trend for innovation, an essential factor for:

- the economic sustainability and employment growth in the life sciences sector;
- the capability of this sector to answer major societal challenges.

\ WALLONIA REGION TECHNOLOGY DEVELOPMENT DEPARTMENT



Through its **Technology Development Department**, **the Wallonia Region** has designed a series of incentives to boost regional innovation and research and to meet the needs of all companies, from start-ups to well-established enterprises. Wallonia's R&D incentives include:

- Grants for basic industrial research (up to 80% R&D costs):
- Other possibilities includes grants for feasibility studies or patent deposits.

Place de la Wallonie 1 • BE-5100 NAMUR T +32 81 33 45 62

www. recherche-technologie. wallonie. be

Delegates: Alain DE MOL, Life Science Advisor • alain.demol@spw.wallonie.be

Josée HUTSCHEMACKERS, Life Science Advisor • josee.hutschemackers@spw.wallonie.be

\ TRADE & INVESTMENT OFFICES

ATLANTA

Wim VAN CAUTEREN (Brussels & Flanders) atlanta@fitagency.com

BOSTON

Maxime VAN CAUTER (Wallonia - Technology Attaché) m.vancauter@wbi.be

CHICAGO

Gilles Philippart de FOY (Wallonia) chicago@awex-wallonia.com

Jean-Pierre VASAUNE (Wallonia - Investment) jpvasaune@investinwallonia.com

Piet MORISSE (Flanders & Brussels) chicago@fitagency.com

Claude STOMP (Flanders - Investment) chicago@fitagency.com

HOUSTON

Yves DUBUS (Brussels & Wallonia) houston@awex-wallonia.com Heidi HOOVER (Flanders) houston@fitagency.com

LOS ANGELES & SAN FRANCISCO

Baudouin de HEMPTINNE (Wallonia) sanfrancisco@awex-wallonia.com
Eric GABRYS (Brussels) california@brusselsinvestexport.com
Raphaël PAUWELS (Flanders) losangeles@fitagency.com
Wim SOHIER (Flanders - Technology Attaché) wim.sohier@fitagency.com

NEW YORK

Luc LIPPENS (Brussels)newyork@brusselsinvestexport.comEdith MAYEUX (Wallonia)newyork@awex-wallonia.comBenoit REINARDS (Flanders - Investment)newyork@fitagency.comLuc STRYBOL (Flanders)newyork@fitagency.comJan WAUTERS (Flanders - Technology Attaché)jan.wauters@fitagency.com

WASHINGTON

Bernard GEENEN (Brussels & Wallonia) washington@awex-wallonia.com

BELGIUM@BIO USA
JUNE 19-22, 2017

\ NOTES



\ NOTES

| | | | | | | | | | | | | | |
|------|------|---------|-------------|---------|---------|---------|-----|-------------|---------|------|---------|---------------|--|
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | • • • | | | | | • • | | | | | | |
| | | | | | | | | | | | | | |
| | | • • • • | | • • • • | • • • • | | | • • • • | • • • • | | • • • • | • • • • • | |
| | | • • • • | | • • • • | • • • • | | | • • • • | • • • • | | • • • • | • • • • • | |
| | | • • • | | | • • • • | • • • • | | • • • • | • • • • | | | • • • • • | |
| | | • • • | | | • • • • | | | • • • • | • • • • | | | • • • • • | |
| | | • • • | • • • • | • • • • | • • • • | | | • • • • | • • • • | | • • • • | • • • • • | |
| | | • • • | • • • • | • • • • | • • • • | | | • • • • | • • • • | | • • • • | • • • • • | |
| | | • • • | • • • • | • • • • | • • • • | | | • • • • | • • • • | | • • • • | • • • • • | |
| | | • • • | | | | | | • • • • | | | | • • • • • | |
| | | • • • | | | | | | • • • • | | | | • • • • • | |
| | | • • • | | | | | | • • • • | | | | • • • • • | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |

